A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects

A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra®) in Chinese healthy subjects

AbstractPurpose QX003S is a biosimilar candidate for the reference tocilizumab, Actemra®. We investigated the tolerance, variability, and pharmacokinetics (PK) of QX003S biosimilar in healthy Chinese male subjects.Design A randomised, double-blind, two-arm, parallel study was performed to examine th...

Full description

Bibliographic Details
Main Authors: Hong Zhang, Xiaojiao Li, Jingrui Liu, Cuiyun Li, Min Wu, Xiaoxue Zhu, Jixuan Sun, Min Fang, Yanhua Ding
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Annals of Medicine
Subjects:
Tocilizumab
biosimilar
immunogenicity
pharmacokinetics
inter-subject variability
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2021.1887925

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2021.1887925

Similar Items